Rational design of a nanoparticle platform for oral prophylactic immunotherapy to prevent immunogenicity of therapeutic proteins.
Sci Rep
; 11(1): 17853, 2021 09 08.
Article
em En
| MEDLINE
| ID: mdl-34497305
ABSTRACT
The safety and efficacy of several life-saving therapeutic proteins are compromised due to their immunogenicity. Once a sustained immune response against a protein-based therapy is established, clinical options that are safe and cost-effective become limited. Prevention of immunogenicity of therapeutic proteins prior to their initial use is critical as it is often difficult to reverse an established immune response. Here, we discuss a rational design and testing of a phosphatidylserine-containing nanoparticle platform for novel oral prophylactic reverse vaccination approach, i.e., pre-treatment of a therapeutic protein in the presence of nanoparticles to prevent immunogenicity of protein therapies.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Nanopartículas
/
Imunoterapia
Limite:
Animals
Idioma:
En
Ano de publicação:
2021
Tipo de documento:
Article